Search results for "PHARMACOKINETICS"

showing 10 items of 458 documents

1023 – Therapeutic drug-monitoring of bupropion for depression

2013

Introduction Therapeutic Drug-Monitoring (TDM) for bupropion is limited by bupropion's instability at room temperature and by the absence of a well-defined therapeutic reference range. Further it is unclear to what extent bupropion and its metabolites contribute to therapeutic effects, though hydroxybupropion seems to account for the major antidepressant effects. Aim The aim of this examination was to check if measurement of only hydroxybupropion is useful to guide the antidepressant therapy with bupropion. Methods Hydroxybupropion plasma levels were measured by high performance liquid chromatography with ultra violet detection and related to therapeutic effects measured by the Clinical Glo…

Bupropionmedicine.diagnostic_testbusiness.industryTherapeutic effectReference rangeHydroxybupropionPharmacologyPsychiatry and Mental healthPharmacokineticsTherapeutic drug monitoringAnesthesiamedicineClinical Global ImpressionAntidepressantbusinessmedicine.drugEuropean Psychiatry
researchProduct

A systematic review and combined analysis of therapeutic drug monitoring studies for longacting risperidone

2017

Introduction: This systematic review of therapeutic drug monitoring (TDM) identifies three long-acting injectable (LAI) risperidone formulations. Areas covered: Limited data is available on two formulations (RBP-7000 and in Situ Microparticle), but 20 TDM articles on the microsphere formulation were found. Risperidone TDM includes the serum concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, used for calculating: 1) the risperidone/9-hydroxyrisperidone (R/9-OH-R) ratio (a measure of CYP2D6; values >1 are indicative of a CYP2D6 poor metabolizer) and 2) the total risperidone concentration-to-dose (C/D) ratio (a measure of risperidone clearance with a normal value…

CYP2D6Therapeutic drug monitoring studiesAdministration OralPharmacologyMicrosphereInjections03 medical and health sciences0302 clinical medicineLong acting risperidonePaliperidone PalmitatemedicineAnimalsHumansPharmacology (medical)General Pharmacology Toxicology and Pharmaceutics610 Medicine & healthActive metabolitePaliperidone PalmitateRisperidonemedicine.diagnostic_testbusiness.industryGeneral MedicineRisperidoneMicrospheres030227 psychiatryAntipsychotic agents/administration & dosage; delayed-action preparations; drug monitoring; injections; risperidone/administration & dosage; risperidone/blood; risperidone/metabolism; risperidone/pharmacokinetics; risperidone/pharmacology; risperidone/therapeutic use; schizophrenia/drug therapyTherapeutic drug monitoringDelayed-Action PreparationsDrug Monitoringbusiness030217 neurology & neurosurgerymedicine.drugAntipsychotic Agents
researchProduct

PHEA-graft-polymethacrylate supramolecular aggregates for protein oral delivery

2013

Abstract Salmon calcitonin (sCT) is characterized by a poor oral availability. A new copolymer, β-poly(N-2-hydroxyethyl)-graft-{N-2-ethylene[2-poly(methacrylic acid sodium salt)isobutyrate]}- d , l -aspartamide (PHEA-IB-p(MANa + )), was designed for the oral administration of sCT through the formation of supramolecular aggregates (SAs) based on electrostatic interactions. Several sCT/PHEA-IB-p(MANa + ) weight ratios were characterized by turbidimetry, DLS, zeta potential, and microscopy analysis. After the incubation of sCT/PHEA-IB-p(MANa + ) complex with digestive enzymes, 10% (w/w) of loaded sCT was released in the native form. In vitro investigation was carried out to determine the copol…

Calcitoninmedicine.medical_specialtypeptide deliveryAdministration OralPharmaceutical Sciencechemistry.chemical_elementPeptidePharmacologyCalciumRats Sprague-DawleyRandom AllocationDrug Delivery SystemsPolymethacrylic AcidsPharmacokineticsimmune system diseasesOral administrationhemic and lymphatic diseasesmedicineAnimalsHumansPolyhydroxyethyl Methacrylatechemistry.chemical_classificationDrug CarriersGeneral Medicineoral deliveryRatsBioavailabilitySurgeryoral delivery; peptide delivery; calcitoninsurgical procedures operativechemistryCalcitoninSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoPharmacodynamicsFemaleTurbidimetryCaco-2 CellsPeptidestherapeuticshuman activitiesPHEA oral delivery osteoporosis supramolecolar aggregates peptide almon calcitoninBiotechnology
researchProduct

Whole-body pharmacokinetics of HDAC inhibitor drugs, butyric acid, valproic acid and 4-phenylbutyric acid measured with carbon-11 labeled analogs by …

2013

The fatty acids, n-butyric acid (BA), 4-phenylbutyric acid (PBA) and valproic acid (VPA, 2-propylpentanoic acid) have been used for many years in the treatment of a variety of CNS and peripheral organ diseases including cancer. New information that these drugs alter epigenetic processes through their inhibition of histone deacetylases (HDACs) has renewed interest in their biodistribution and pharmacokinetics and the relationship of these properties to their therapeutic and side effect profiles. In order to determine the pharmacokinetics and biodistribution of these drugs in primates, we synthesized their carbon-11 labeled analogues and performed dynamic positron emission tomography (PET) in…

Cancer ResearchBiodistributionSide effectPharmacologyPhenylbutyrateArticleButyric acidchemistry.chemical_compoundPharmacokineticsmedicineAnimalsRadiology Nuclear Medicine and imagingTissue DistributionCarbon RadioisotopesValproic AcidRadiochemistryValproic AcidBrainLipid metabolismBlood ProteinsBlood proteinsPhenylbutyratesHistone Deacetylase InhibitorschemistryIsotope LabelingPositron-Emission TomographyMolecular MedicineButyric AcidFemalemedicine.drugPapio
researchProduct

Impact of Undernutrition on the Pharmacokinetics and Pharmacodynamics of Anticancer Drugs: A Literature Review

2017

The etiology of undernourishment in cancer patients is multifactorial: tumor-related mechanisms (such as obstruction, metabolic abnormalities, and functionality changes) in addition to the influence of anticancer therapies, which can induce or worsen undernutrition. The evident role of undernutrition in cancer treatment outcomes suggests the need of considering nutritional status when evaluating anticancer drugs. In order to merge the available data and offer researchers and clinicians a global view of this phenomenon, the present manuscript reviews on a drug-by-drug basis the undernutrition-related pharmacokinetic and pharmacodynamic aspects of anticancer treatments. This review notes inte…

Cancer ResearchMedicine (miscellaneous)Antineoplastic AgentsPharmacologyBioinformatics030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicineOtotoxicityPharmacokineticsmedicineHumansAnthracyclinesDosingVinca AlkaloidsEtoposideCardiotoxicityNutrition and Dieteticsbusiness.industryMalnutritionNeurotoxicitymedicine.diseaseCancer treatmentMalnutritionMethotrexateOncology030220 oncology & carcinogenesisFluorouracilPharmacodynamic aspectsbusinessNutrition and Cancer
researchProduct

Abstract B154: A first-in-human trial of GDC-0068: A novel, oral, ATP-competitive Akt inhibitor, demonstrates robust suppression of the Akt pathway i…

2011

Abstract GDC-0068 is a highly selective ATP-competitive small molecule that inhibits all three isoforms of Akt with IC50 values of 5 to 30 nM. GDC-0068 selectively inhibits cancer cells with activated Akt signaling (e.g. via PTEN loss or PIK3CA mutations). Patients with advanced solid tumors were treated with GDC-0068 using a 3+3 escalation design. GDC-0068 was dosed PO QD on a 21-day on, 7-day off schedule; endpoints included safety, pharmacokinetics (PK) and determination of pathway knockdown. Pharmacodynamics (PD) endpoints in surrogate tissue [platelet rich plasma (PRP)] were evaluated in all patients. In addition, at least two patients per cohort had pre- and on-treatment (day 15) tumo…

Cancer Researchbiologymedicine.diagnostic_testChemistryCancerPharmacologymedicine.diseaseOncologyPharmacokineticsPharmacodynamicsBiopsyCancer cellbiology.proteinmedicinePTENProtein kinase BPI3K/AKT/mTOR pathwayMolecular Cancer Therapeutics
researchProduct

Abstract CT109: A phase I/Ib study evaluating GDC-0077 plus fulvestrant in patients with PIK3CA-mutant, hormone receptor-positive/HER2-negative breas…

2020

Abstract Background: PIK3CA encodes the PI3K p110α subunit, and dysregulating mutations are widely seen in breast cancer (BC) and other solid tumors. GDC-0077 (G) is a potent p110α-selective inhibitor that degrades mutant p110α and demonstrates antitumor activity in PIK3CA-mutant BC xenograft models, either as a single agent, or combined with anti-estrogen therapy. From an ongoing, open-label, phase I/Ib dose-escalation study of G alone and combined with endocrine + targeted therapies (NCT03006172), we present data of G + fulvestrant (F) in postmenopausal patients (pts) with PIK3CA-mutant, hormone receptor-positive/HER2-negative BC, including a food-effect assessment on the pharmacokinetics…

Cancer Researchmedicine.medical_specialtyFulvestrantbusiness.industryCumulative doseCmaxCancermedicine.diseaseGastroenterologyDysgeusiaBreast cancerOncologyPharmacokineticsPharmacodynamicsInternal medicinemedicinemedicine.symptombusinessmedicine.drugCancer Research
researchProduct

Abstract CT-08: A Phase 1 study of MEHD7945A (MEHD), a first-in-class EGFR/HER3 dual action antibody, in patients (pts) with locally advanced or meta…

2012

Abstract Background Dysregulated human epidermal growth factor receptor tyrosine kinase (HER RTK) signaling is an important driver of tumor growth, metastasis, and survival. Extensive HER RTK co-expression and heterodimerization suggest that simultaneous blockade of multiple RTKs may be more effective than targeting individual RTKs, and may help prevent or delay development of resistance mechanisms. MEHD is a novel dual-action human IgG1 antibody. Each antigen-binding fragment blocks ligand binding to both EGFR and HER3, which is meant to inhibit the activity of the major ligand-dependent HER dimers in cancer. MEHD also elicits antibody-dependent cell-mediated cytotoxicity, and has single-a…

Cancer Researchmedicine.medical_specialtybusiness.industryNauseaCancermedicine.diseaseRashGastroenterologyMetastasisOncologyPharmacokineticsInternal medicineImmunologyToxicitymedicineChillsmedicine.symptombusinessAdverse effectCancer Research
researchProduct

Synthesis and PET studies of [11C-cyano]letrozole (Femara®), an aromatase inhibitor drug

2009

Abstract Introduction Aromatase, a member of the cytochrome P 450 family, converts androgens such as androstenedione and testosterone into estrone and estradiol, respectively. Letrozole (1-[bis-(4-cyanophenyl)methyl]-1 H -1,2,4-triazole; Femara) is a high-affinity aromatase inhibitor ( K i =11.5 nM) that has Food and Drug Administration approval for breast cancer treatment. Here we report the synthesis of carbon-11-labeled letrozole and its assessment as a radiotracer for brain aromatase in the baboon. Methods Letrozole and its precursor (4-[(4-bromophenyl)-1 H -1,2,4-triazol-1-ylmethyl]benzonitrile) were prepared in a two-step synthesis from 4-cyanobenzyl bromide and 4-bromobenzyl bromide,…

Cancer Researchmedicine.medical_specialtymedicine.drug_classEstronePharmacologyArticlechemistry.chemical_compoundAromatasePharmacokineticsInternal medicineNitrilesmedicineAnimalsRadiology Nuclear Medicine and imagingAndrostenedioneCarbon RadioisotopesAromataseTestosteroneAromatase inhibitorbiologyChemistryAromatase InhibitorsLetrozoleBrainTriazolesEndocrinologyFree fractionIsotope LabelingPositron-Emission TomographyLetrozolebiology.proteinMolecular MedicineFemaleRadiopharmaceuticalsmedicine.drugPapio
researchProduct

The isolated perfused rat brain as a model for studying drugs acting on the CNS

1974

An isolated perfused brain preparation is regarded as offering some important advantages over intact animals or tissue slices for studying drug effects on the CNS. The rat is by far the most suitable laboratory animal for this technique because of low cost, ease of preparation and extensive literature available for comparative purposes. In this paper various preparation techniques and perfusion systems for an isolated rat brain are reported. Investigations are presented proving the viability of the isolated perfused rat brain for more than seven hours and its suitability for studies on cerebral metabolism. Until now this preparation has been successfully used for pharmacological investigati…

Central Nervous SystemDrugmedia_common.quotation_subjectCentral nervous systemPharmacology toxicologyDrug Evaluation PreclinicalEnergy metabolismCerebral metabolismIn Vitro TechniquesBiologyPharmacologyOxygen ConsumptionPharmacokineticsMethodsmedicineAnimalsmedia_commonPharmacologyBrainElectroencephalographyRat brainRatsPerfusionmedicine.anatomical_structurePerfusionNeurosciencePsychopharmacologia
researchProduct